

PC¹

International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, C07K 7/10	A1	(11) International Publication Number: WO 96/23513 (43) International Publication Date: 8 August 1996 (08.08.96)
<p>(21) International Application Number: PCT/US96/00946</p> <p>(22) International Filing Date: 29 January 1996 (29.01.96)</p> <p>(30) Priority Data: 08/381,661 31 January 1995 (31.01.95) US 08/384,292 6 February 1995 (06.02.95) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/384,292 (CIP) Filed on 6 February 1995 (06.02.95)</p> <p>(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 462885 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BASINSKI, Margaret, B. [US/US]; 1229 North Hawthorne Lane, Indianapolis, IN 46219 (US). DIMARCHI, Richard, D. [US/US]; 10890 Wilmington Drive, Carmel, IN 46033 (US). HEATH, William, F., Jr. [US/US]; 11214 Tufton Street, Fishers, IN 46038 (US). SCHONER, Brigitte, E. [US/US]; R.R.2, Box 30 F, Monrovia, IN 46157 (US).</p>	<p>(74) Agents: CALTRIDER, Steven, P. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	

(54) Title: **ANTI-OBESITY PROTEINS**

(57) Abstract

The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.

BEST AVAILABLE COPY